Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC280 with or without erlotinib versus platinum/pemetrexed in EGFR-mutant, cMET-amplified NSCLC after EGFR TKI resistance
NL-OMON42451Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing INC280 monotherapy, INC280 plus erlotinib and Platinum plus pemetrexed (3 arms). Primary endpoints: Maximum tolerated dose, Recommended phase II dose and 1 more. Started Jan 2016; status: active, not recruiting.
02
Drugs
capmatiniberlotinibpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON42451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42451.